Enlibrium Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $15M
Latest Deal Amount
  • Investors
  • 4

Enlibrium General Information


Developer of novel drugs designed to treat a range of different cancers. The company's novel drugs are based on metformin that reduces cancer energy consumption and reestablishes energy balance.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • San Diego, CA
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Enlibrium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 03-Dec-2015 $15M 0000 0000 Completed Startup
To view Enlibrium’s complete valuation and funding history, request access »

Enlibrium Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.0 00.0 00 00.0 000
To view Enlibrium’s complete cap table history, request access »

Enlibrium Executive Team (3)

Name Title Board Seat Contact Info
Michael Jung Ph.D Co-Founder
Richard Pietras Ph.D Co-Founder
To view Enlibrium’s complete executive team members history, request access »

Enlibrium Board Members (2)

Name Representing Role Since
Heather Preston MD TPG Biotech Board Member 000 0000
Jay Lichter Ph.D Avalon Ventures Board Member 000 0000
To view Enlibrium’s complete board members history, request access »

Enlibrium Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Avalon Ventures Venture Capital Minority 000 0000 000000 0
Correlation Ventures Venture Capital Minority 000 0000 000000 0
Osage University Partners Venture Capital Minority 000 0000 000000 0
TPG Biotech Venture Capital Minority 000 0000 000000 0
To view Enlibrium’s complete investors history, request access »